Carregant...
Value of Adaptive Trials and Surrogate Endpoints for Clinical Decision-Making in Rare Cancers
Despite high-level endorsement, the number of adaptive Phase II/III trials in rare cancers needs to be improved, with better understanding of their value for clinical decisions in daily practice. This paper describes approaches to trial design in rare cancers, which has been supplemented by a search...
Guardat en:
| Publicat a: | Front Oncol |
|---|---|
| Autors principals: | , , |
| Format: | Artigo |
| Idioma: | Inglês |
| Publicat: |
Frontiers Media S.A.
2021
|
| Matèries: | |
| Accés en línia: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7982798/ https://ncbi.nlm.nih.gov/pubmed/33763370 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3389/fonc.2021.636561 |
| Etiquetes: |
Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|